Aribio-Related Stocks Plunge... Market Remains 'Unimpressed' Despite AR1001 Phase 3 Results [Stock NOW]
- Input
- 2026-11-17 09:17:16
- Updated
- 2026-11-17 09:17:16

[Financial News] Aribio is developing the oral Alzheimer's disease drug candidate AR1001. Although the company disclosed results from its global Phase 3 clinical trial, the market response has been cool.
A statistically significant effect was observed in the monotherapy group, whose members were not taking existing dementia treatments. But the overall patient population did not achieve statistical significance, prompting assessments that the results fell short of expectations.
As of 9:09 a.m. on the 17th, shares of listed companies associated with Aribio were plunging across the board on the KOSDAQ (Korea Securities Dealers Automated Quotations). The stock shown on screen as Aribio Lab traded at 4,400 won, down 1,410 won (24.27%) from the previous trading day's close. ARIBIO Holdings was also down 485 won (13.29%) at 3,165 won. Selling pressure appeared concentrated in related stocks immediately after the clinical trial results were disclosed.
The key finding was that treatment effects differed by patient group. On the 16th local time, Aribio disclosed the 52-week results of its global Phase 3 trial, POLARIS-AD, at the Clinical Trials on Alzheimer's Disease conference (CTAD 2026) in Boston, United States.
The trial compared the effects of once-daily doses of 30 mg of AR1001 or a placebo over 52 weeks in 1,535 patients with early Alzheimer's disease.
Positive results were seen in the 604-patient monotherapy group, which was not taking existing Alzheimer's disease treatments alongside the study drug. Based on the primary endpoint, the Clinical Dementia Rating–Sum of Boxes (CDR-SB), AR1001 slowed the rate of symptom worsening by 31% compared with placebo. The adjusted mean difference was -0.44 points, with a p-value of 0.0266, meeting the prespecified significance level of 0.03.
By contrast, statistical significance was not achieved in the overall population of 1,535 patients. The adjusted mean difference in CDR-SB scores between the AR1001 and placebo groups was just -0.11 points, with a p-value of 0.4015.
Although the figures favored the drug group, the treatment effect was not statistically proven. The effect on delaying symptom worsening in the overall population was estimated at around 7%.
Statistical significance was also not achieved on the key secondary measures assessing cognitive function and the ability to perform daily activities. Some measures in the monotherapy group showed a trend toward improvement, but analysts say there are limits to how much they support an overall treatment effect.
These results do not completely rule out AR1001's development potential, but the failure to demonstrate an effect in the overall patient population could weigh on expectations for commercialization.
A key question is how much of the effect observed in the monotherapy group will be recognized in real-world prescribing and during the approval process.
In terms of safety, the incidence of serious adverse events was similar in the AR1001 and placebo groups, at 10.0% and 9.8%, respectively. However, the proportion of patients who stopped taking the drug because of adverse events was higher in the AR1001 group, at 5.2%, than in the placebo group, at 1.7%. The incidence of some adverse events, including diarrhea and falls, was also higher than in the placebo group.
The financial investment industry expects market attention to ultimately focus on how much weight the effect observed in the monotherapy group can carry as evidence in future approval and commercialization processes.
[email protected] Kang Jung-mo Reporter